The downregulation of DYNLL1 is significantly correlated with poor progression-free survival in patients with BRCA1-mutated ovarian carcinomas undergoing platinum-based chemotherapy (He and Meghani and Caron and Yang and Ronato and Bian and Sharma and Moore and Niraj and Detappe and Doench and Legube and Root and D’Andrea and Drane and De and Konstantinopoulos and Masson and Chowdhury 2018). Here, DYNLL1 is linked to ovarian carcinoma.